5连板杭电股份：光通信业务亏损；天士力：普佑克新增适应症获批丨公告精选

Group 1 - Changchuan Technology expects a net profit of 827 million to 877 million yuan for the first three quarters of 2025, representing a year-on-year growth of 131% to 145% due to strong market demand in the semiconductor industry [1] - Tianqi Materials' subsidiary signed an agreement with Ruipu Lanjun for the supply of at least 800,000 tons of electrolyte products until December 31, 2030, with a minimum monthly supply of 20,000 tons [2] - Zhixiang Jintai entered into exclusive cooperation agreements with Kangzhe Pharmaceutical for two monoclonal antibody injection products, securing upfront and milestone payments totaling approximately 510 million yuan [2] Group 2 - Hangdian Co. reported that its optical communication business is currently in a loss state, while its copper foil business is still in the early stages of development [3] - Guangli Micro announced an inquiry transfer price of 65 yuan per share, which is a 28% discount from the closing price, with 24 institutional investors participating in the inquiry [4] - Tianshili's subsidiary received approval for a new indication for its recombinant human urokinase product, making it the only approved product of its kind in China [5] Group 3 - Kairun Co. plans to acquire 20% of Shanghai Jiale for 280 million yuan through its wholly-owned subsidiary [6] - Sanyou Medical's shareholder QM5 LIMITED intends to transfer 6.67 million shares, accounting for 2% of the total share capital [7] - Various companies, including Youxunda and Xinyuan Zhizao, are expected to win bids for projects with the State Grid, with total bid amounts ranging from approximately 5.58 million to 1.93 billion yuan [7]